191 related articles for article (PubMed ID: 18791114)
1. Natalizumab and PML: a risky business?
Clifford DB
Gut; 2008 Oct; 57(10):1347-9. PubMed ID: 18791114
[No Abstract] [Full Text] [Related]
2. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
Tyler KL; Khalili K
Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
[No Abstract] [Full Text] [Related]
3. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
4. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
Achiron A; Miron S; Shoenfeld Y
Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
[No Abstract] [Full Text] [Related]
5. Reply to "'Thinking without thinking' about natalizumab and PML".
Houff S; Berger JR
J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
[No Abstract] [Full Text] [Related]
6. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
Berger JR; Koralnik IJ
N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
[No Abstract] [Full Text] [Related]
10. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
[TBL] [Abstract][Full Text] [Related]
13. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab for relapsing multiple sclerosis.
Meyer MA
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
[No Abstract] [Full Text] [Related]
16. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
17. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major EO
N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
[No Abstract] [Full Text] [Related]
18. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
19. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
